Hydroxychloroquine dose based upon weight and renal function

Discussion in 'Discount Prescription Drugs From Canada' started by inoe.name, 17-Mar-2020.

  1. dmitryus XenForo Moderator

    Hydroxychloroquine dose based upon weight and renal function


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Plaquenil sjogren's pregnancy Plaquenil and color vision

    Detailed Hydroxychloroquine dosage information for adults and children. Systemic Lupus Erythematosus, Malaria Prophylaxis and more; plus renal, liver and dialysis adjustments. Detailed Hydroxychloroquine dosage information for adults and children. Alternate dosing based on body weight A total dose representing 25 mg/kg is administered. Regarding the dosing of hydroxychloroquine, we advocate the use of a weight-based dosing regimen with a cap at 400 mg per day, except in the case of renal insufficiency, when the dose should be reduced to 200 mg per day and for those on dialysis, who should take their hydroxychloroquine at 200 mg three times per week. Aug 30, 2011 Risk factors that increase the chance of hydroxychloroquine retinopathy include daily dosage, cumulative dose, renal or liver disease, age, and previous retinal disease 9. A daily dose of 6.5mg/kg ideal body weight places patients at higher risk, but a daily dose below this level did not preclude the patient from developing toxicity after.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Hydroxychloroquine dose based upon weight and renal function

    Plaquenil Hydroxychloroquine Uses, Dosage, Side Effects., RheumNow Hydroxychloroquine Blood Levels in SLE MedPage.

  2. Hydroxychloroquine ayuda a disminuir el dolor
  3. Plaquenil eye exam optometrist or ophthalmologist
  4. Regarding the dosing of hydroxychloroquine, we advocate the use of a weight based dosing regimen with a cap at 400 mg per day, except in the case of renal insufficiency, when the dose should be reduced to 200 mg per day and for those on dialysis, who should take their hydroxychloroquine, 200 mg three times per week.

    • The Role of Hydroxychloroquine Blood Levels in SLE..
    • Hydroxychloroquine Plaquenil Toxicity and Recommendations..
    • Renal Function-Based Dose Adjustments - Adult - Inpatient..

    Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. Weight-based dosing in adults and pediatric patients 6.5 mg/kg 5 mg/kg base. PLAQUENIL- hydroxychloroquine sulfate tablet Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg 5 mg/kg base of actual body weight, durations of use greater than five years, subnormal glomerular filtration. Hydroxychloroquine retinopathy is most influenced by daily dose and duration of use. Risk for toxicity is less with 5.0 mg/kg real weight/day for hydroxychloroquine and 2.3 mg/kg real weight/day for chloroquine. Patients are at low risk during the first 5 years of treatment.

     
  5. barm Well-Known Member

    Plaquenil (hydroxychloroquine) belongs to a group of medicines called quinolines. How lupus affects the eyes Lupus Foundation of America Lid Swelling Linked to Lupus? Hydroxychloroquine Oral Route Side Effects - Mayo Clinic
     
  6. ColonelTY Well-Known Member

    13 mg/kg (10 mg/kg base), not to exceed 800 mg (620 mg base) followed by 6.5 mg/kg (5 mg/kg base), not to exceed 400 mg (310 mg base), at 6 hours, 24 hours and 48 hours after the initial dose. PowerPoint. Update on Plaquenil Testing Plaquenil Dosage Guide - My Take on New Ocular Screening Guidelines for Plaquenil.
     
  7. Resfi Well-Known Member

    Discontinued Plaquenil.other options? The alternative to Plaquenil is a slightly different anti malarial called Quinacrine. Plaquenil replaced Quinacrine formerly called Atabrine for anti malarial prophylaxis so now the Quinacrine has to be made up into pills or gel capsules by a compounding pharmacy. If you google you will find details of compounding pharmacies.

    Side Effects of Plaquenil Hydroxychloroquine, Warnings, Uses